Dr. Vokes on PARP Inhibitors for NSCLC

Everett Vokes, MD
Published: Monday, Aug 28, 2017



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses PARP inhibitors for patients with non-small cell lung cancer (NSCLC).

PARP inhibtors are currently being investigated in many different tumor types. Some PARP inhibitors are partially approved in breast and ovarian cancer, where they have been shown to be superior to some chemotherapy regimens, explains Vokes.

Since lung cancer has repair defects in DNA repair pathways, PARP inhibitors could possibly improve progression-free survival for patients with NSCLC.



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses PARP inhibitors for patients with non-small cell lung cancer (NSCLC).

PARP inhibtors are currently being investigated in many different tumor types. Some PARP inhibitors are partially approved in breast and ovarian cancer, where they have been shown to be superior to some chemotherapy regimens, explains Vokes.

Since lung cancer has repair defects in DNA repair pathways, PARP inhibitors could possibly improve progression-free survival for patients with NSCLC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x